NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis $10.70 +0.04 (+0.38%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.58▼$11.0050-Day Range$8.37▼$12.6652-Week Range$7.61▼$14.27Volume608,685 shsAverage Volume889,736 shsMarket Capitalization$1.46 billionP/E RatioN/ADividend YieldN/APrice Target$34.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vir Biotechnology alerts: Email Address Vir Biotechnology MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside217.8% Upside$34.00 Price TargetShort InterestBearish5.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.19Based on 5 Articles This WeekInsider TradingSelling Shares$43,800 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.57) to ($3.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.12 out of 5 starsMedical Sector613th out of 936 stocksBiological Products, Except Diagnostic Industry97th out of 154 stocks 3.2 Analyst's Opinion Consensus RatingVir Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageVir Biotechnology has only been the subject of 4 research reports in the past 90 days.Read more about Vir Biotechnology's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.32% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Vir Biotechnology has recently decreased by 0.21%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIR. Previous Next 1.8 News and Social Media Coverage News SentimentVir Biotechnology has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Vir Biotechnology this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,800.00 in company stock.Percentage Held by Insiders15.60% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vir Biotechnology's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vir Biotechnology are expected to decrease in the coming year, from ($3.57) to ($3.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vir Biotechnology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Vir Biotechnology Stock (NASDAQ:VIR)Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.Read More VIR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIR Stock News HeadlinesJuly 26 at 6:53 PM | msn.comVir Biotechnology Stock Reaches 80-Plus RS Rating BenchmarkJuly 21, 2024 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives $34.14 Average PT from BrokeragesJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 20, 2024 | msn.comStudy reveals a promising approach to developing universal influenza vaccineJuly 20, 2024 | msn.comUniversal flu jab ‘could be available within five years’July 20, 2024 | msn.comVaccine created from 1918 Spanish flu may protect against all strains, study findsJuly 20, 2024 | bizjournals.comOHSU-developed 'one and done' flu vaccine could become a reality in five yearsJuly 19, 2024 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) versus Coeptis Therapeutics (NASDAQ:COEP) Head to Head SurveyJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 17, 2024 | seekingalpha.comBullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And HepatitisJuly 4, 2024 | investorplace.com3 Undervalued Biotech Gems With 200%+ Analyst Price TargetsJune 5, 2024 | businesswire.comTobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of TreatmentMay 29, 2024 | finance.yahoo.comVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | businesswire.comVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | msn.comResearchers discover vaccine originally created for HIV may also combat cancerMay 29, 2024 | markets.businessinsider.comVir Biotechnology Appoints Mark Eisner As EVP And Chief Medical OfficerMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology on Promising CHD and CHB Program ProspectsMay 24, 2024 | markets.businessinsider.comEvaluating Vir Biotechnology: Insights From 5 Financial AnalystsSee More Headlines Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIR CUSIPN/A CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees587Year FoundedN/APrice Target and Rating Average Stock Price Target$34.00 High Stock Price Target$110.00 Low Stock Price Target$12.00 Potential Upside/Downside+217.8%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-615,060,000.00 Net Margins-677.69% Pretax Margin-690.97% Return on Equity-32.58% Return on Assets-26.97% Debt Debt-to-Equity RatioN/A Current Ratio12.90 Quick Ratio12.90 Sales & Book Value Annual Sales$43.99 million Price / Sales33.10 Cash FlowN/A Price / Cash FlowN/A Book Value$11.82 per share Price / Book0.91Miscellaneous Outstanding Shares136,059,000Free Float114,834,000Market Cap$1.46 billion OptionableOptionable Beta0.48 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Marianne De Backer M.B.A. (Age 55)M.Sc., Ph.D., CEO & Director Comp: $4.47MMr. Sung H. Lee (Age 54)Executive VP & CFO Comp: $968.45kDr. Ann M. Hanly Ph.D. (Age 54)Executive VP & Chief Technology Officer Comp: $896.07kDr. Jeff Calcagno M.D. (Age 63)Executive VP & Chief Business Officer Comp: $860.49kDr. Klaus Frueh Ph.D. (Age 64)Co-Founder & Scientific Advisor Comp: $177.66kDr. Lawrence Corey M.D. (Age 76)Co-Founder & Scientific Advisor Dr. Louis J. Picker M.D.Co-Founder & Scientific AdvisorDr. Jennifer Eileen Towne Ph.D.Executive VP & Chief Scientific OfficerMs. Heather Rowe ArmstrongVice President of Investor RelationsMs. Vanina De Verneuil J.D.Executive VP, General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsFate TherapeuticsNASDAQ:FATEbluebird bioNASDAQ:BLUEChina Biologic ProductsNASDAQ:CBPOCRISPR TherapeuticsNASDAQ:CRSPImmunovantNASDAQ:IMVTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 6,359 shares on 7/26/2024Ownership: 0.598%Baillie Gifford & Co.Sold 25,823 shares on 7/25/2024Ownership: 2.882%Louisiana State Employees Retirement SystemBought 1,200 shares on 7/24/2024Ownership: 0.032%Saira RamasastrySold 4,000 sharesTotal: $43,800.00 ($10.95/share)Tidal Investments LLCBought 34,750 shares on 5/17/2024Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions VIR Stock Analysis - Frequently Asked Questions How have VIR shares performed this year? Vir Biotechnology's stock was trading at $10.06 at the beginning of the year. Since then, VIR stock has increased by 6.4% and is now trading at $10.70. View the best growth stocks for 2024 here. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) issued its earnings results on Thursday, May, 2nd. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.51. The business's quarterly revenue was down 10.5% on a year-over-year basis. What is George Scangos' approval rating as Vir Biotechnology's CEO? 7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Top institutional investors of Vir Biotechnology include Baillie Gifford & Co. (2.88%), Bank of New York Mellon Corp (0.60%) and Louisiana State Employees Retirement System (0.03%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Phillip Pang, Howard Horn, Johanna Friedl-Naderer, Ann M Hanly, George A Scangos, Steven J Rice, Sung Lee, Saira Ramasastry, Charles Elliott Sigal, Janet Napolitano and Herbert Virgin. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIR) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
